Remove Artificial Inteligence Remove San Diego Remove Tool Remove Venture Capital
article thumbnail

Erasca Raises $64M For Oncology Drug Development Using AI

socalTECH

San Diego-based Erasca , a company which is using artificial intelligence to drive the discovery and development of new oncology drugs to help cure cancer, has raised $64M in a Series A funding, the company said this morning. According to the company, the new funding will to towards.

article thumbnail

Five Questions With a16z’s Vijay Pande on AI and Making New Drugs

Xconomy

Those toolsartificial intelligence and machine learning, respectively—have been around for decades, but in recent years have become faster and cheaper, accelerating their use by those in the business of discovering and developing new drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Saxena: More Than a Tool, A.I. Must Be Used With Society in Mind

Xconomy

[ Updated 12/27/18, 9:54 am ] Manoj Saxena is bullish on artificial intelligence. startup CognitiveScale and managing director of The Entrepreneur Fund , which makes investments in early-stage machine learning companies, Saxena believes A.I. As chairman of Austin, TX-based A.I.

article thumbnail

Reveal Biosciences Gets Intel’s Backing on “AI-Powered” Pathology

Xconomy

A 25-person startup developing advanced computing tools to speed up pathology work has raised its first institutional financing from a group of investors led by Intel Capital, the corporate investment arm of the chipmaker.

article thumbnail

Startups Peddle Innovative Tools to Fight Tech’s #MeToo Problem

Xconomy

Now, some founders are seeking to use tech tools such as chatbots, artificial intelligence, analytics, and mobile to help clients remedy those deficiencies. As the last year has shown, the tech industry has a significant problem with sexual harassment and ensuring that women are treated equitably in the workplace.

article thumbnail

Empirico Raises $17M, Inks 3-Year Antisense Collaboration with Ionis

Xconomy

Empirico, a biotech that has developed tools to analyze genomics data and use those insights to identify potential therapeutic targets, has signed a collaboration deal with antisense drug developer Ionis Pharmaceuticals that includes a $10 million equity investment. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

article thumbnail

Austin Group Joins Other Tech Efforts to Promote Responsible AI Use

Xconomy

Artificial intelligence is poised to infiltrate nearly all aspects of human life. Given this development, technologists are focusing on how to ensure the technology usage is governed by ethics. The general rule is that power begets responsibility,” says Michael Stewart, founder and CEO of Lucid AI , an AI startup in Austin. “If